2. Search Result
Search Result
Results for "

broad spectrum anticancer

" in MedChemExpress (MCE) Product Catalog:

46

Inhibitors & Agonists

1

Screening Libraries

1

Peptides

9

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151374
    3-IN-PP1

    		PKD Cancer
    3-IN-PP1 is a protein kinase D (PKD) inhibitor. 3-IN-PP1 has potent pan-PKD inhibitory activity for PKD1, PKD2 and PKD3 with IC50 values of 108, 94 and 108 nM, respectively. 3-IN-PP1 also is a broad spectrum anticancer agent and has inhibition of several tumor cells growth. 3-IN-PP1 can be used for the research of cancer .
    3-IN-PP1
  • HY-N0275
    (±)-10-Hydroxycamptothecin

    (±)-10-HCPT

    		 Topoisomerase Cancer
    (±)-10-Hydroxycamptothecin is an indole alkaloid that inhibits the activity of topoisomerase I and has a broad spectrum of anticancer activity.
    (±)-10-Hydroxycamptothecin
  • HY-139635
    Anticancer agent 11

    		DNA Alkylator/Crosslinker Cancer
    Anticancer agent 11 is a broad-spectrum anticancer agent that inhibits angiogenesis and induces DNA cross-links.
    Anticancer agent 11
  • HY-147822
    Apoptosis inducer 6

    		Apoptosis Cancer
    Apoptosis inducer 6 (compound 4e) is an anticancer agent with a broad-spectrum anticancer activity. Apoptosis inducer 6 triggers cell death through the induction of apoptosis .
    Apoptosis inducer 6
  • HY-146358
    Anticancer agent 49

    		Microtubule/Tubulin Cancer
    Anticancer agent 49 (compound 69) is a broad spectrum anticancer agent. Anticancer agent 49 inhibits tubulin polymerization. Anticancer agent 49 shows antiproliferative activity. Anticancer agent 49 has the potential for the research of solid and hematological tumors .
    Anticancer agent 49
  • HY-146357
    Anticancer agent 48

    		Microtubule/Tubulin Cancer
    Anticancer agent 48 (compound 48) is a broad spectrum anticancer agent. Anticancer agent 48 inhibits tubulin polymerization. Anticancer agent 48 shows antiproliferative activity. Anticancer agent 48 shows antitumor activity in vivo. Anticancer agent 48 has the potential for the research of solid and hematological tumors .
    Anticancer agent 48
  • HY-B0134
    Bestatin
    5+ Cited Publications

    Ubenimex

    		 Aminopeptidase Bacterial Antibiotic Infection Cancer
    Bestatin is a natural, broad-spectrum, and competitive CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase inhibitor. Bestatin has anticancer effects .
    Bestatin
  • HY-16394
    PG-11047 tetrahydrochloride

    CGC-11047 tetrahydrochloride

    		 Others Cancer
    PG-11047 (CGC-11047), a polyamine analogue, is a nonfunctional competitor of the natural polyamine spermine. PG-11047 has broad spectrum anticancer activities .
    PG-11047 tetrahydrochloride
  • HY-156777
    Antiproliferative agent-36

    		Others Cancer
    Antiproliferative agent-36 (compound 8i) is a benzothiazolyl hydrazones derived compound with antiproliferative activity. Antiproliferative agent-36 has a broad-spectrum anticancer activity .
    Antiproliferative agent-36
  • HY-N0565A
    Doxycycline hydrochloride
    60+ Cited Publications

    		 MMP Bacterial Antibiotic Parasite Infection Cancer
    Doxycycline hydrochloride, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor . Doxycycline hydrochloride shows antibacterial activity and anti-cancer cell proliferation activity .
    Doxycycline hydrochloride
  • HY-N0565
    Doxycycline
    60+ Cited Publications

    		 MMP Bacterial Antibiotic Parasite Infection Cancer
    Doxycycline, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor . Doxycycline shows antibacterial activity and anti-cancer cell proliferation activity .
    Doxycycline
  • HY-151632
    hCAIX-IN-15

    		Carbonic Anhydrase Cancer
    hCAIX-IN-15 is a potent hCA IX inhibitor with a Ki value of 38.8 nM. hCAIX-IN-15 shows good broad-spectrum anticancer activity and can be used for cancer research .
    hCAIX-IN-15
  • HY-15287
    Nelfinavir
    10+ Cited Publications

    AG1341

    		 HIV Protease HIV Infection Cancer
    Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent .
    Nelfinavir
  • HY-155570
    Anticancer agent 137

    		PI3K Apoptosis Caspase PARP Cancer
    Anticancer agent 137 (8q) is a potent PI3k inhibitor. Anticancer agent 137 has broad-spectrum anticancer activity. Anticancer agent 137 induces G2/M cell cycle arrest and apoptosis. Anticancer agent 137 increases cleaved PARP, caspase 3, and 7. Anticancer agent 137 can be used in research of cancer .
    Anticancer agent 137
  • HY-15287A
    Nelfinavir Mesylate
    10+ Cited Publications

    AG 1343 Mesylate

    		 HIV Protease HIV Infection Cancer
    Nelfinavir Mesylate (AG 1343 Mesylate) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir Mesylate (AG 1343 Mesylate) is a broad-spectrum, anticancer agent .
    Nelfinavir Mesylate
  • HY-N0565B
    Doxycycline hyclate
    60+ Cited Publications

    Doxycycline hydrochloride hemiethanolate hemihydrate; WC2031

    		 Antibiotic MMP Bacterial Parasite Infection Cancer
    Doxycycline hyclate, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor . Doxycycline hyclate shows antibacterial activity and anti-cancer cell proliferation activity .
    Doxycycline hyclate
  • HY-N0565C
    Doxycycline calcium

    		MMP Bacterial Antibiotic Parasite Infection Cancer
    Doxycycline calcium, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor . Doxycycline calcium shows antibacterial activity and anti-cancer cell proliferation activity .
    Doxycycline calcium
  • HY-158061
    Topoisomerase II inhibitor 20

    		Topoisomerase Apoptosis Cancer
    Topoisomerase II inhibitor 20 (Compound 3e) is a potent topoisomerase II (Topoisomerase II) inhibitor with an IC50 of 0.98 µM. Topoisomerase II inhibitor 20 induces apoptosis and has broad-spectrum anticancer activity .
    Topoisomerase II inhibitor 20
  • HY-108016
    Peruvoside

    Encordin

    		 Src PI3K JNK STAT EGFR Apoptosis Autophagy Cancer
    Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib .
    Peruvoside
  • HY-113064
    Selenocystine

    		Endogenous Metabolite Cancer
    Selenocystine is a broad-spectrum anti-cancer agent. Selenocystine induces DNA damage in HepG2 cells, particularly in the form of DNA double strand breaks (DSBs). Selenocystine exhibits great promise as a therapeutic or adjuvant agent targeting DNA repair for cancer treatment .
    Selenocystine
  • HY-163114
    2-Stearoxyphenethyl phosphocholin

    		p38 MAPK Metabolic Disease
    2-Stearoxyphenethyl phosphocholin (compound 1a) is a p38 MAPK inhibitor with anticancer activity. 2-Stearoxyphenethyl phosphocholin may bind to the p38 MAPK lipid-binding pocket and has broad-spectrum anti-tumor and lipid-modulating activities .
    2-Stearoxyphenethyl phosphocholin
  • HY-163115
    2-Oleoxyphenethyl phosphocholin

    		p38 MAPK Cancer
    2-Oleoxyphenethyl phosphocholin (compound 1b) is a p38 MAPK inhibitor with anticancer activity. 2-Oleoxyphenethyl phosphocholin may bind to the p38 MAPK lipid-binding pocket and has broad-spectrum anti-tumor and lipid-modulating activities .
    2-Oleoxyphenethyl phosphocholin
  • HY-151161
    EGFR/HER2-IN-8

    		EGFR Cancer
    EGFR/HER2-IN-8 (compound 34) is a EGFR/HER2 and DHFR inhibitor. EGFR/HER2-IN-8 inhibits EGFR kinase, HER2 kinase and DHFR with IC50s of 0.45, 0.244 and 5.669 μM, respectively. EGFR/HER2-IN-8 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer .
    EGFR/HER2-IN-8
  • HY-151156
    EGFR/HER2-IN-6

    		EGFR Apoptosis Cancer
    EGFR/HER2-IN-6 (compound 43) is an EGFR/HER2 and DHFR inhibitor. EGFR/HER2-IN-6 inhibits EGFR kinase, HER2 kinase and DHFR with IC50s of 0.122, 0.078 and 0.585 μM, respectively. EGFR/HER2-IN-6 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer .
    EGFR/HER2-IN-6
  • HY-N2491
    Deoxyelephantopin

    		NF-κB Cancer
    Deoxyelephantopin, a natural bioactive sesquiterpene lactone from Elephantopus scaber, has shown promising anticancer effects against a broad spectrum of cancers. Deoxyelephantopin inhibits NF-κB, MAPK, PI3K/Akt, and β-catenin signaling .
    Deoxyelephantopin
  • HY-15287S1
    Nelfinavir-d4

    		HIV HIV Protease Isotope-Labeled Compounds Infection Cancer
    Nelfinavir-d4 is deuterated labeled Nelfinavir (HY-15287). Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent .
    Nelfinavir-d4
  • HY-N6746
    Citrinin

    NSC 186

    		 Bacterial Fungal Endogenous Metabolite Infection Neurological Disease Cancer
    Citrinin is a mycotoxin which causes contamination in the food and is associated with different toxic effects. Citrinin is usually found together with another nephrotoxic mycotoxin, Ochratoxin A. Citrinin is also reported to possess a broad spectrum of bioactivities, including antibacterial, antifungal, and potential anticancer and neuro-protective effects in vitro .
    Citrinin
  • HY-157990
    Wnt/β-catenin-IN-1

    		Wnt β-catenin Cancer
    Wnt/β-catenin-in-1 (compounds 17) is a Wnt/β-catenin signaling pathway inhibitor. Wnt/β-catenin-IN-1 can induce apoptosis of colon cancer cells, has broad-spectrum anticancer activity, and can be used for the reseach of a variety of solid tumors .
    Wnt/β-catenin-IN-1
  • HY-161144
    AKT-IN-21

    		Akt Apoptosis Cancer
    AKT-IN-21 (compound C36) is a potent AKT inhibitor with broad-spectrum cytotoxicity and anticancer activity. AKT-IN-21 also blocks the cell cycle and induces apoptosis of cancer cells by down-regulating the PI3K/AKT pathway .
    AKT-IN-21
  • HY-15287S
    Nelfinavir-d3

    		Isotope-Labeled Compounds HIV Protease HIV Infection Cancer
    Nelfinavir-d3 (AG1341-d3) is the deuterium labeled Nelfinavir. Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent[1][2][3].
    Nelfinavir-d3
  • HY-N2949
    Bonducellpin D

    		SARS-CoV Infection Cancer
    Bonducellpin D is a furanoditerpenoid lactone isolated from Caesalpinia minax. Bonducellpin D exhibits broad-spectrum inhibition potential against SARS-CoV M pro and MERS-CoV M pro, with an Ki of 467.11 and 284.86 nM, respectively. Bonducellpin D also exhibits moderate anti-cancer activity in vitro .
    Bonducellpin D
  • HY-10969
    Obatoclax Mesylate
    5+ Cited Publications

    GX15-070 Mesylate

    		 Bcl-2 Family Autophagy Parasite Infection Cancer
    Obatoclax Mesylate (GX15-070 Mesylate), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a Ki of 220 nM for BCL-2 . Obatoclax Mesylate induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax Mesylate has anti-cancer and broad-spectrum antiparasitic activity .
    Obatoclax Mesylate
  • HY-B0450
    Ciclopirox
    4 Publications Verification

    HOE296b

    		 Fungal Bacterial Ferroptosis Autophagy Infection Inflammation/Immunology Cancer
    Ciclopirox (HOE296b) is a synthetic and orally active antifungal agent that can be used for superficial mycoses reseaech. Ciclopirox olamine has a very broad spectrum of activity and inhibits dermatophytes, yeasts, molds, and many Gram-positive and Gram-negative species pathogenic. Ciclopirox also has anticancer and anti-inflammatory effect .
    Ciclopirox
  • HY-B0450A
    Ciclopirox olamine
    4 Publications Verification

    Ciclopirox ethanolamine; HOE 296

    		 Fungal Bacterial Ferroptosis Infection Cancer
    Ciclopirox olamine (Ciclopirox ethanolamine) is a synthetic and orally active antifungal agent that can be used for superficial mycoses reseaech. Ciclopirox olamine has a very broad spectrum of activity and inhibits dermatophytes, yeasts, molds, and many Gram-positive and Gram-negative species pathogenic. Ciclopirox olamine also has anticancer and anti-inflammatory effect .
    Ciclopirox olamine
  • HY-10969A
    Obatoclax

    GX15-070

    		 Bcl-2 Family Autophagy Parasite Infection Cancer
    Obatoclax (GX15-070), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a Ki of 220 nM for BCL-2 . Obatoclax induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax has anti-cancer and broad-spectrum antiparasitic activity .
    Obatoclax
  • HY-147864
    c-Fms-IN-12

    		c-Fms c-Kit Apoptosis Cancer
    c-Fms-IN-12 (Compound 4g) is an FMS kinase inhibitor. c-Fms-IN-12 can also inhibits c-KIT. c-Fms-IN-12 is a potential broad-spectrum anticancer agent against multiple cancer types. c-Fms-IN-12 induces A549 cell apoptosis .
    c-Fms-IN-12
  • HY-10254
    Mirdametinib
    80+ Cited Publications

    PD0325901; PD325901

    		 MEK Autophagy Apoptosis Cancer
    Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM. Mirdametinib exhibits a Ki app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts .
    Mirdametinib
  • HY-12098
    Verubulin hydrochloride

    MPC-6827 hydrochloride

    		 Microtubule/Tubulin Cancer
    Verubulin hydrochloride (MPC-6827 hydrochloride) is a blood brain barrier permeable microtubule-disrupting agent, with potent and broad-spectrum in vitro and in vivo cytotoxic activities. Verubulin hydrochloride (MPC-6827 hydrochloride) exhibits potent anticancer activity in human MX-1 breast and other mouse xenograft cancer models. Verubulin hydrochloride (MPC 6827 hydrochloride) is a promising candidate for the treatment of multiple cancer types .
    Verubulin hydrochloride
  • HY-N0372
    Licochalcone A
    5+ Cited Publications

    Licochalcone-A

    		 Autophagy Cancer
    Licochalcone A (LCA), a flavonoid isolated, presents obvious anti-cancer effects, displays broad-spectrum inhibition against UDP-glucuronosyltransferases (UGTs) . Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC50 and Ki values lower than 5 μM) .
    Licochalcone A
  • HY-N6746S1
    Citrinin-13C13

    NSC 186-13C13

    		 Isotope-Labeled Compounds Cancer
    Citrinin- 13C13 (NSC 186- 13C13) is the 13C labeled Citrinin (HY-N6746) . Citrinin is a mycotoxin which causes contamination in the food and is associated with different toxic effects. Citrinin is usually found together with another nephrotoxic mycotoxin, Ochratoxin A. Citrinin is also reported to possess a broad spectrum of bioactivities, including antibacterial, antifungal, and potential anticancer and neuro-protective effects in vitro .
    Citrinin-13C13
  • HY-15142A
    Doxorubicin

    Hydroxydaunorubicin

    		 ADC Cytotoxin Antibiotic Bacterial Topoisomerase AMPK HIV Autophagy Mitophagy Apoptosis HBV Infection Cancer
    Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy . Doxorubicin inhibits human DNA topoisomerase I with an IC50 of 0.8 μM .
    Doxorubicin
  • HY-151630
    hCAIX-IN-16

    		Carbonic Anhydrase Cancer
    hCAIX-IN-16 (Compound 12d) is hCA IX inhibitor, with Ki values of 190.0 and 187.9 nM for hCA IX and hCA XII, respectively. hCAIX-IN-16 can arrest the cell cycle of breast cancer MDA-MB-468 in G0-G1 and S phase and induce apoptosis. hCAIX-IN-16 shows good broad-spectrum anticancer activity and can be used for cancer research .
    hCAIX-IN-16
  • HY-155458
    HYDAMTIQ

    		PARP Inflammation/Immunology Cancer
    HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more .
    HYDAMTIQ
  • HY-10226
    JNJ-16241199

    R306465

    		 Apoptosis HDAC Cancer
    JNJ-16241199 is an orally active, selective hydroxamate-based histone deacetylase (HDAC) inhibitor, with the IC50 of 3.3 nM and 23 nM for HDAC1 and HDAC8, respectively. JNJ-16241199 induces histone 3 acetylation and strongly increases the expression of p21 waf1, cip1 in A2780 ovarian carcinoma cells. JNJ-16241199 induces cell apoptosis and shows anticancer activity in a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .
    JNJ-16241199
  • HY-12843
    Bohemine
    1 Publications Verification

    		 CDK ERK Cancer
    Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC50s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC50 of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities .
    Bohemine
  • HY-149407
    Multi-kinase-IN-4

    		VEGFR CDK EGFR Necroptosis Apoptosis Cancer
    Multi-kinase-IN-4 (compound 5d) is multi-targeted kinase inhibitor, including VEGFR2, EGFR, HER2, and CDK2, with IC50 values of 0.33, 0.22, 0.18 and 2.09 μM, respectively. Multi-kinase-IN-4 shows broad-spectrum anti-cancer activities against HepG2, MCF-7, MDA-231, and HeLa cell lines (IC50 = 1.94–7.1 µM), but exhibits lower toxicity in the WI-38 cells (IC50 = 40.85 µM). Multi-kinase-IN-4 induces apoptosis and arrests cell cycle at S phase in HepG2 cells. Multi-kinase-IN-4 has the potential for the research of cancer .
    Multi-kinase-IN-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: